logo

For the Inventor, By the Inventor

Lexington, MA, United States of America

Dicerna Pharmaceuticals, Inc.


USPTO Granted Patents = 102

% Expired Patents = 8.8



Trademarks = 5

Forward Citations = 398

Loading Chart...
Loading Chart...

37 inventors (with patents filed for the assignee):

goldMedal Bob Dale Brown (79 out of 96 patents)

silverMedal Henryk T Dudek (57 out of 65 patents)

bronzeMedal Marc Abrams (14 out of 15 patents)

4.  Cheng Lai (8 out of 8 patents)

5.  Weimin Wang (7 out of 7 patents)

6.  Utsav Saxena (7 out of 7 patents)

7.  Natalie Wayne Pursell (6 out of 7 patents)

8.  Martin Koser (5 out of 5 patents)

9.  Naim Nazef (5 out of 5 patents)

10.  Shanthi Ganesh (5 out of 6 patents)

11.  Jihye Park (4 out of 5 patents)

12.  Wen Han (4 out of 4 patents)

13.  Anton Turanov (4 out of 4 patents)

14.  Sujit Basu (3 out of 5 patents)

15.  Qingyi Li (2 out of 9 patents)


Core Competencies:
Gene Expression
Hepatitis B
Double-Stranded RNA
Alpha-1 Antitrypsin
Glycolate Oxidase
Lactate Dehydrogenase
CRISPR Technology
Oligonucleotides
Immunotherapy
Nucleic Acid
Antithrombin 3
PCSK9

102 patents:

1. 12735710 - COMPOSITIONS AND METHODS FOR INHIBITING ANGPTL3 EXPRESSION (2026-09-15),
2. 12674169 - Compositions and methods for modulatingactivity (2026-07-07),
3. 12564601 - METHODS FOR TREATING HEPATITIS B INFECTION (2026-03-03),
4. 12435336 - Compositions and methods for inhibiting LPA expression (2025-10-07),
5. 12252691 - Compositions and methods for inhibiting LPA expression (2025-03-18),
6. 12234456 - Compositions and methods for modulating APOC3 expression (2025-02-25),
7. 12084662 - Compositions and methods for modulating PNPLA3 expression (2024-09-10),
8. 12077756 - Extended dicer substrate agents and methods for the specific inhibition of gene expression (2024-09-03),
9. 12037586 - 4'-phosphate analogs and oligonucleotides comprising the same (2024-07-16),
10. 12037358 - Compositions comprising reversibly modified oligonucleotides and uses thereof (2024-07-16),
11. 11952574 - Compositions and methods for inhibiting transmembrane serine protease 6 (TMPRSS6) expression (2024-04-09),
12. 11912996 - Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA (2024-02-27),
13. 11873493 - Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA (2024-01-16),
14. 11873488 - Double-stranded nucleic acid inhibitor molecules modified with Tm-increasing nucleotides (2024-01-16),
15. 11851658 - Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA (2023-12-26),
Dicerna Pharmaceuticals, Inc. is a biotechnology company based in Lexington, MA, specializing in gene expression inhibition. The company focuses on developing innovative therapies targeting diseases linked to gene expression, including hepatitis B and conditions related to alpha-1 antitrypsin deficiency. Dicerna leverages advanced technologies such as double-stranded RNA, CRISPR, and oligonucleotides to create potential treatments that address unmet medical needs, emphasizing precision medicine in its research and development efforts.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Dicerna Pharmaceuticals, Inc.
102 Patents

#8 in Lexington, MA

#201 in Massachusetts

#3,716 in US

#7,641 in the World

Lexington, MA (US)
Lexington, MA, United States of America

Dicerna Pharmaceuticals, Inc.

Forward Citations = 398

37 inventors:

goldMedal Bob Dale Brown (79 out of 96 patents)

silverMedal Henryk T Dudek (57 out of 65 patents)

bronzeMedal Marc Abrams (14 out of 15 patents)

4.  Cheng Lai (8 out of 8 patents)

5.  Weimin Wang (7 out of 7 patents)

Please report any incorrect information to [email protected]
Loading…